130 related articles for article (PubMed ID: 33148516)
1. A highly potent maytansinoid analogue and its use as a cytotoxic therapeutic agent in gold nanoparticles for the treatment of hepatocellular carcinoma.
Porter J; Ding Y; Hale SJM; Perrins RD; Robinson A; Mazanetz MP; Wu Y; Ma Y; Conlon K; Coulter T
Bioorg Med Chem Lett; 2020 Dec; 30(24):127634. PubMed ID: 33148516
[TBL] [Abstract][Full Text] [Related]
2. DM1 Loaded Ultrasmall Gold Nanoparticles Display Significant Efficacy and Improved Tolerability in Murine Models of Hepatocellular Carcinoma.
Hale SJM; Perrins RD; Garcı A CE; Pace A; Peral U; Patel KR; Robinson A; Williams P; Ding Y; Saito G; Rodriguez MÁ; Perera I; Barrientos A; Conlon K; Damment S; Porter J; Coulter T
Bioconjug Chem; 2019 Mar; 30(3):703-713. PubMed ID: 30582799
[TBL] [Abstract][Full Text] [Related]
3. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
[TBL] [Abstract][Full Text] [Related]
4. Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity.
Wang H; Wu J; Xu L; Xie K; Chen C; Dong Y
Chem Commun (Camb); 2017 Feb; 53(17):2618-2621. PubMed ID: 28195282
[TBL] [Abstract][Full Text] [Related]
5. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.
Oroudjev E; Lopus M; Wilson L; Audette C; Provenzano C; Erickson H; Kovtun Y; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2700-13. PubMed ID: 20937595
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
7. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules.
Lopus M; Oroudjev E; Wilson L; Wilhelm S; Widdison W; Chari R; Jordan MA
Mol Cancer Ther; 2010 Oct; 9(10):2689-99. PubMed ID: 20937594
[TBL] [Abstract][Full Text] [Related]
8. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma.
Raoof M; Corr SJ; Zhu C; Cisneros BT; Kaluarachchi WD; Phounsavath S; Wilson LJ; Curley SA
Nanomedicine; 2014 Aug; 10(6):1121-30. PubMed ID: 24650884
[TBL] [Abstract][Full Text] [Related]
9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles Encapsulating Nitrosylated Maytansine To Enhance Radiation Therapy.
Gao S; Zhang W; Wang R; Hopkins SP; Spagnoli JC; Racin M; Bai L; Li L; Jiang W; Yang X; Lee C; Nagata K; Howerth EW; Handa H; Xie J; Ma Q; Kumar A
ACS Nano; 2020 Feb; 14(2):1468-1481. PubMed ID: 31939662
[TBL] [Abstract][Full Text] [Related]
11. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
12. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
14. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
[TBL] [Abstract][Full Text] [Related]
15. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
16. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
[TBL] [Abstract][Full Text] [Related]
18. C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.
Li W; Huang M; Li Y; Xia A; Tan L; Zhang Z; Wang Y; Yang J
Biochem Biophys Res Commun; 2021 Aug; 566():197-203. PubMed ID: 34144258
[TBL] [Abstract][Full Text] [Related]
19. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
20. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
